Division of Gastroenterology and Hepatology, Department of Medicine, New York University Grossman School of Medicine, New York, New York; Division of Environmental Health Sciences, University of Minnesota School of Public Health, Minneapolis, Minnesota.
Division of Gastroenterology, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts.
Gastroenterology. 2022 Sep;163(3):732-741. doi: 10.1053/j.gastro.2022.05.028. Epub 2022 May 25.
BACKGROUND & AIMS: Colonoscopy for colorectal cancer screening is endoscopist dependent, and colonoscopy quality improvement programs aim to improve efficacy. This study evaluated the clinical benefit and safety of using a computer-aided detection (CADe) device in colonoscopy procedures.
This randomized study prospectively evaluated the use of a CADe device at 5 academic and community centers by US board-certified gastroenterologists (n = 22). Participants aged ≥40 scheduled for screening or surveillance (≥3 years) colonoscopy were included; exclusion criteria included incomplete procedure, diagnostic indication, inflammatory bowel disease, and familial adenomatous polyposis. Patients were randomized by endoscopist to the standard or CADe colonoscopy arm using computer-generated, random-block method. The 2 primary endpoints were adenomas per colonoscopy (APC), the total number of adenomas resected divided by the total number of colonoscopies; and true histology rate (THR), the proportion of resections with clinically significant histology divided by the total number of polyp resections. The primary analysis used a modified intention-to-treat approach.
Between January and September 2021, 1440 participants were enrolled to be randomized. After exclusion of participants who did not meet the eligibility criteria, 677 in the standard arm and 682 in the CADe arm were included in a modified intention-to-treat analysis. APC increased significantly with use of the CADe device (standard vs CADe: 0.83 vs 1.05, P = .002; total number of adenomas, 562 vs 719). There was no decrease in THR with use of the CADe device (standard vs CADe: 71.7% vs 67.4%, P for noninferiority < .001; total number of non-neoplastic lesions, 284 vs 375). Adenoma detection rate was 43.9% and 47.8% in the standard and CADe arms, respectively (P = .065).
For experienced endoscopists performing screening and surveillance colonoscopies in the United States, the CADe device statistically improved overall adenoma detection (APC) without a concomitant increase in resection of non-neoplastic lesions (THR).
gov registration: NCT04754347.
结直肠癌筛查用结肠镜检查依赖于内镜医生,结肠镜质量改进计划旨在提高疗效。本研究评估了在结肠镜检查中使用计算机辅助检测(CADe)设备的临床获益和安全性。
这项前瞻性随机研究评估了美国委员会认证的胃肠病学家在 5 个学术和社区中心使用 CADe 设备(n=22)的情况。纳入年龄≥40 岁、接受筛查或监测(≥3 年)结肠镜检查的患者;排除标准包括检查不完整、诊断指征、炎症性肠病和家族性腺瘤性息肉病。患者由内镜医生按照计算机生成的随机区组法随机分配到标准或 CADe 结肠镜组。主要终点为每例结肠镜检查检出的腺瘤数(APC),即切除的腺瘤总数除以结肠镜检查总数;真组织学检出率(THR),即有临床意义的组织学切除的比例除以息肉切除总数。主要分析采用改良意向治疗方法。
2021 年 1 月至 9 月期间,共纳入 1440 名符合条件的参与者进行随机分组。排除不符合入选标准的参与者后,677 名参与者纳入标准组,682 名参与者纳入 CADe 组,采用改良意向治疗分析。使用 CADe 设备后,APC 显著增加(标准组 vs CADe 组:0.83 vs 1.05,P=.002;腺瘤总数:562 个 vs 719 个)。使用 CADe 设备并未降低 THR(标准组 vs CADe 组:71.7% vs 67.4%,非劣效性 P<.001;非肿瘤性病变总数:284 个 vs 375 个)。标准组和 CADe 组的腺瘤检出率分别为 43.9%和 47.8%(P=.065)。
对于在美国进行筛查和监测结肠镜检查的经验丰富的内镜医生,CADe 设备在统计学上提高了总体腺瘤检出率(APC),但并未增加非肿瘤性病变(THR)的切除率。
gov 注册:NCT04754347。